Volastra Therapeutics: Funding, Investors & Team (Sep 2026)
Volastra Therapeutics is a biotechnology company that is creating new treatments for metastatic cancer by leveraging specific knowledge about chromosomal instability.
Volastra Therapeutics has raised $105M across 3 funding rounds on record, the most recent an undisclosed round of $30.1M announced in Sep 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Volastra Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2025.
Volastra Therapeutics Funding Rounds
Volastra Therapeutics raised $60.0M in a Series A announced in Mar 2023.
1.2 years later, an undisclosed round of $15.0M was announced in May 2024.
1.3 years later, an undisclosed round of $30.1M was announced in Sep 2025.
Volastra Therapeutics Founders and Leadership Team
Contact details for the Volastra Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Volastra Therapeutics Funding Compared to Other Biotechnology Startups
Volastra Therapeutics' latest round of $30.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Volastra Therapeutics in Biotechnology and New York
Companies Similar to Volastra Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Volastra Therapeutics Funding FAQs
What does Volastra Therapeutics do?
Volastra Therapeutics is a biotechnology company that is creating new treatments for metastatic cancer by leveraging specific knowledge about chromosomal instability.
How much funding has Volastra Therapeutics raised?
Volastra Therapeutics has raised $105M across 3 rounds on record. The most recent is an undisclosed round of $30.1M announced in Sep 2025.
When did Volastra Therapeutics last raise funding?
Volastra Therapeutics' most recent funding round on record is an undisclosed round of $30.1M, announced in Sep 2025.
Who founded Volastra Therapeutics?
FundedIQ lists Samuel Bakhoum (Founder) at Volastra Therapeutics.
Who is the CEO of Volastra Therapeutics?
David P. Southwell is listed as CEO at Volastra Therapeutics.
Where is Volastra Therapeutics headquartered?
Volastra Therapeutics is based in New York, United States.
How many employees does Volastra Therapeutics have?
Volastra Therapeutics is in the 11-50 employee band.
How does Volastra Therapeutics' funding compare to other Biotechnology startups?
Volastra Therapeutics' latest round of $30.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Volastra Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Volastra Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.